Related Experiment Video
Updated: Jan 20, 2026
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Antiretroviral therapy regimens for neuro-AIDS
1Department of Neurology, Heinrich Heine University, Düsseldorf, Postfach 10 10 07, D-40001 Düsseldorf, Germany. arendtg@uni-duesseldorf.de
Insights
Highly active antiretroviral therapy (HAART) helps prevent human immunodeficiency virus (HIV-1) central nervous system (CNS) disease. Certain HAART drugs show therapeutic effects, but some patients require different interventions for optimal brain health.
Area of Science:
- Neuroscience
- Virology
- Pharmacology
Background:
- The central nervous system (CNS) is a sanctuary site for human immunodeficiency virus type 1 (HIV-1).
- HIV-1-associated brain diseases significantly impact patient prognosis and survival.
- Effective CNS-directed therapies are crucial for managing HIV-1 infection.
Purpose of the Study:
- To evaluate the neuroprophylactic and therapeutic value of highly active antiretroviral therapy (HAART) components against HIV-1 CNS disease.
- To identify optimal therapeutic strategies for HIV-1-associated neurological complications.
- To address the need for prophylactic and therapeutic interventions targeting the CNS in HIV-1 patients.
Main Methods:
- Review of existing studies on HAART efficacy in preventing and treating HIV-1 CNS disease.
- Analysis of cerebrospinal fluid penetration and therapeutic effects of nucleoside analogues (NAs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
- Identification of patient subgroups with specific treatment needs based on viral load and neurological status.
Main Results:
- HAART demonstrates neuroprophylactic value in preventing HIV-1 CNS disease.
- Specific NAs (zidovudine, stavudine) and NNRTIs (nevirapine, efavirenz) show CNS therapeutic effects.
- Adding a second NA offers no additional therapeutic benefit; some patients require alternative interventions.
Conclusions:
- HAART plays a vital role in neuroprotection against HIV-1.
- Current therapeutic options are effective for many, but a subset of patients requires tailored treatment strategies.
- Combination therapy with two NAs and one NNRTI is suggested for patients with high viral loads and neurological abnormalities; PI efficacy requires further evaluation.
Abstract:
In the era of highly active antiretroviral therapy (HAART) the central nervous system (CNS) becomes increasingly important as a sanctuary site for the human immunodeficiency virus (HIV-1). HIV-1-associated brain disease is subdivided into the minor cognitive/motor disorder, the minor cognitive/motor complex and the AIDS dementia complex, all of which are predictive for patients' deaths. CNS effective therapy therefore influences the prognosis of each individual patient. Thus, there is urgent need both for prophylactic and therapeutic strategies preventing or treating HIV-1-associated CNS disease. HAART consisting of two nucleoside analogues (NAs), one or two protease inhibitors (PIs) and/or one non-nucleoside inhibitor of the reverse transcriptase (NNRTI) has a neuroprophylactic value with regard to the manifestation of HIV-I associated CNS disease. With regard to therapeutic effects, the NAs zidovudine and stavudine penetrate into the cerebrospinal fluid and positively influence HIV-1-associated brain disease. Adding a second NA has no additional therapeutic effect. NNRTIs (nevirapine and efavirenz) are also CNS effective. However, there is a subgroup of non-responders, who obviously need other forms of therapeutic interventions. The very few existing studies point out that patients with high plasma viral loads and neurological abnormalities should be treated with a combination of two NAs and one NNRTI. The value of PIs for CNS protection remains to be evaluated.
Related Concept Videos
06:07Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
09:44Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
11:39The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
18:46Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
04:19Oral Combinational Antiretroviral Therapy to Treat HIV-1 Infection in a Humanized Mouse Model
01:15Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...